TransMedics Group, Inc. reported $668M of revenue over the trailing twelve months, +26% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $668M (to Q2 2026). Net income: $152M, trailing twelve months to Q2 2026. Free cash flow: $79M, trailing twelve months to Q2 2026. Operating margin: 12%, trailing twelve months to Q2 2026.

TMDXTransMedics Group, Inc.

Healthcare

$77.81-36% 1Y

$77.81

$62.0452 weeks$150.42

TMDX as reported

TransMedics Group, Inc. reported $668M of revenue over the trailing twelve months, +26% on the year before. 11 reported series are charted on this page, each one as filed.

$668M

Revenue, trailing twelve months · to Q2 2026 · +26% against the twelve months before

Net income: $152M
Net income · +112% year on year · trailing twelve months to Q2 2026
Free cash flow: $79M
Free cash flow · +356% year on year · trailing twelve months to Q2 2026
Operating margin: 12%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for TMDX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$668M	+26%	Q2 2026
Net income	$152M	+112%	Q2 2026
EPS	$3.86	+99%	Q2 2026
Gross margin	59%	n/a	Q2 2026
Operating margin	12%	n/a	Q2 2026
Net margin	24%	n/a	Q2 2026
ROE	33%	n/a	Q2 2026
ROA	12%	n/a	Q2 2026
ROIC	−291%	n/a	Q2 2026
Free cash flow	$79M	+356%	Q2 2026
P/E	20.2	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.